About: Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.03 (-11.43%)
PASG NASDAQ Passage Bio Inc
Passage Bio Inc share price
PASG price activity
Last Price
$4.030
Change (24hr)
-0.52 USD (-11.43%)
Volume
4.29K
Volume (4w avg)
-
Open
$4.46
Day Range
$3.87 - $4.46
Previous Close
$4.55
Last Trade
13 Oct, 4:07 pm GMT+0
Delayed
13 Oct, 4:07 pm GMT+0
PASG price performance
Delayed
13 Oct, 4:07 pm GMT+0
PASG Market Signals